Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2018 Jan;110(1):30-35.
doi: 10.5935/abc.20170180.

Prevalence of Dyslipidemias in Three Regions in Venezuela: The VEMSOLS Study Results

[Article in English, Portuguese]
Affiliations
Observational Study

Prevalence of Dyslipidemias in Three Regions in Venezuela: The VEMSOLS Study Results

[Article in English, Portuguese]
Juan P González-Rivas et al. Arq Bras Cardiol. 2018 Jan.

Abstract

Background: The prevalence of dyslipidemia in multiple regions of Venezuela is unknown. The Venezuelan Metabolic Syndrome, Obesity and Lifestyle Study (VEMSOLS) was undertaken to evaluate cardiometabolic risk factors in Venezuela.

Objective: To determine the prevalence of dyslipidemia in five populations from three regions of Venezuela.

Methods: During the years 2006 to 2010, 1320 subjects aged 20 years or older were selected by multistage stratified random sampling from all households in five municipalities from 3 regions of Venezuela: Lara State (Western region), Merida State (Andean region), and Capital District (Capital region). Anthropometric measurements and biochemical analysis were obtained from each participant. Dyslipidemia was defined according to the NCEP/ATPIII definitions.

Results: Mean age was 44.8 ± 0.39 years and 68.5% were females. The prevalence of lipids abnormalities related to the metabolic syndrome (low HDL-c [58.6%; 95% CI 54.9 - 62.1] and elevated triglycerides [39.7%; 36.1 - 43.2]) were the most prevalent lipid alterations, followed by atherogenic dyslipidemia (25.9%; 22.7 - 29.1), elevated LDL-c (23.3%; 20.2 - 26.4), hypercholesterolemia (22.2%; 19.2 - 25.2), and mix dyslipidemia (8.9%; 6.8 - 11.0). Dyslipidemia was more prevalent with increasing body mass index.

Conclusion: Dyslipidemias are prevalent cardiometabolic risk factors in Venezuela. Among these, a higher prevalence of low HDL is a condition also consistently reported in Latin America.

PubMed Disclaimer

Conflict of interest statement

Potential Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Figures

Figure 1
Figure 1
Prevalence of dyslipidemia by nutritional status. *Difference in the prevalence of dyslipidemia according to nutritional status using Chi-square (p < 0.01). High triglycerides: 150 mg/dL; low HDL-c: < 40 mg/dL in men and < 50 mg/dL in women; atherogenic dyslipidemia: triglycerides = 150 mg/dL + low HDL-c; hypercholesterolemia: total cholesterol = 240 mg/dL; elevated LDL-c: = 160 mg/dL; mixed dyslipidemia: triglycerides = 150 + total cholesterol = 240 mg/dL.
Figure 2
Figure 2
Prevalence of dyslipidemias by abdominal obesity (waist circumference = 94 cm in men and = 90 cm in women). Significant difference of the prevalence of dyslipidemia between abdominal obesity or normal waist circumference *(p < 0.001) †(p = 0.002). High triglycerides = 150 mg/dL; Low HDL-c < 40 mg/dL in men and < 50 mg/dL in women; Atherogenic dyslipidemia triglycerides =150 mg/dL + low HDL-c; Hypercholesterolemia =240 mg/dL; Elevated LDL-c = 160 mg/dL; Mix dyslipidemia triglycerides = 150 + cholesterol = 240 mg/dL.

Similar articles

Cited by

References

    1. World Health Organization Global Health Observatory Data Repository country views. [2015 Aug 6]. Venezuela (Bolivarian Republic of) statistics summary (2002 - present) [Internet] Available from: http://apps.who.int/gho/data/node.country.country-VEN?lang=en.
    1. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–952. doi: 10.1016/S0140-6736(04)17018-9. - DOI - PubMed
    1. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. INTERSTROKE investigators Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376(9735):112–123. doi: 10.1016/S0140-6736(10)60834-3. - DOI - PubMed
    1. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Cholesterol Treatment Trialists'. Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681. doi: 10.1016/S0140-6736(10)61350-5. - DOI - PMC - PubMed
    1. Nieto-Martinez R, Hamdy O, Marante D, Marulanda MI, Marchetti A, Hegazi RA, et al. Transcultural diabetes nutrition algorithm (tDNA): Venezuelan application. Nutrients. 2014;6(4):1333–1363. doi: 10.3390/nu6041333. - DOI - PMC - PubMed

Publication types